New combo therapy targets recurrent ovarian cancer
NCT ID NCT03734692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for women whose ovarian cancer has come back. It combines chemotherapy and immunotherapy given directly into the abdomen with a drug given through a vein. The goal is to see if this approach can shrink or eliminate tumors. The study involves 24 participants and is currently active but not recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
- Blood protein map may reveal hidden clues in ovarian cancer treatment
- Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
- Promising combo for Hard-to-Treat ovarian cancer never got off the ground
- Engineered immune cells take on tough ovarian cancer in first human trial
- Can surgery buy more time for ovarian cancer patients?